Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).
Identifieur interne : 001A31 ( Main/Corpus ); précédent : 001A30; suivant : 001A32Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).
Auteurs : Ritesh Gupta ; Anoop MisraSource :
- Diabetes & metabolic syndrome [ 1878-0334 ]
English descriptors
- KwdEn :
- Betacoronavirus (MeSH), COVID-19 (MeSH), Comorbidity (MeSH), Coronavirus Infections (complications), Coronavirus Infections (drug therapy), Diabetes Complications (MeSH), Diabetes Mellitus (drug therapy), Diabetes Mellitus (epidemiology), Humans (MeSH), Hypertension (drug therapy), Hypertension (epidemiology), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH).
- MESH :
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Diabetes Mellitus, Hypertension, Pneumonia, Viral.
- epidemiology : Diabetes Mellitus, Hypertension.
- Betacoronavirus, COVID-19, Comorbidity, Diabetes Complications, Humans, Pandemics, SARS-CoV-2.
Abstract
BACKGROUND AND AIMS
Multiple issues in management of COVID have emerged, but confusion persists regarding rational interpretation. Aim of this brief review is to review these issues based on current literature.
METHODS
This is a narrative review with Pubmed and Google Scholar search till 23 March 2020. Search terms were, COVID-19, treatment of coronavirus, COVID 19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers, cardiovascular disease, diarrhoea, liver, testis and gastrointestinal disease.
RESULTS
We discuss evidence regarding role of chloroquine and hydroxychloroquine in treatment and prophylaxis, use of inhibitors of the renin angiotensin system, safety of ibuprofen, unusual clinical features like gastrointestinal symptoms and interpretation of tests for cardiac enzymes and biomarkers.
CONCLUSIONS
While our conclusions on management of COVID-19 patients with co-morbidities are based on current evidence, however, data is limited and there is immediate need for fast track research.
DOI: 10.1016/j.dsx.2020.03.012
PubMed: 32247213
PubMed Central: PMC7102586
Links to Exploration step
pubmed:32247213Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).</title><author><name sortKey="Gupta, Ritesh" sort="Gupta, Ritesh" uniqKey="Gupta R" first="Ritesh" last="Gupta">Ritesh Gupta</name><affiliation><nlm:affiliation>Fortis CDOC Hospital, Chirag Enclave, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Misra, Anoop" sort="Misra, Anoop" uniqKey="Misra A" first="Anoop" last="Misra">Anoop Misra</name><affiliation><nlm:affiliation>Fortis CDOC Hospital, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India. Electronic address: anoopmisra@gmail.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 May - Jun</date><idno type="RBID">pubmed:32247213</idno><idno type="pmid">32247213</idno><idno type="doi">10.1016/j.dsx.2020.03.012</idno><idno type="pmc">PMC7102586</idno><idno type="wicri:Area/Main/Corpus">001A31</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001A31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).</title><author><name sortKey="Gupta, Ritesh" sort="Gupta, Ritesh" uniqKey="Gupta R" first="Ritesh" last="Gupta">Ritesh Gupta</name><affiliation><nlm:affiliation>Fortis CDOC Hospital, Chirag Enclave, New Delhi, India.</nlm:affiliation></affiliation></author><author><name sortKey="Misra, Anoop" sort="Misra, Anoop" uniqKey="Misra A" first="Anoop" last="Misra">Anoop Misra</name><affiliation><nlm:affiliation>Fortis CDOC Hospital, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India. Electronic address: anoopmisra@gmail.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Diabetes & metabolic syndrome</title><idno type="eISSN">1878-0334</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Comorbidity (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (drug therapy)</term><term>Diabetes Complications (MeSH)</term><term>Diabetes Mellitus (drug therapy)</term><term>Diabetes Mellitus (epidemiology)</term><term>Humans (MeSH)</term><term>Hypertension (drug therapy)</term><term>Hypertension (epidemiology)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Diabetes Mellitus</term><term>Hypertension</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Diabetes Mellitus</term><term>Hypertension</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Comorbidity</term><term>Diabetes Complications</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND AND AIMS</b></p><p>Multiple issues in management of COVID have emerged, but confusion persists regarding rational interpretation. Aim of this brief review is to review these issues based on current literature.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>This is a narrative review with Pubmed and Google Scholar search till 23 March 2020. Search terms were, COVID-19, treatment of coronavirus, COVID 19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers, cardiovascular disease, diarrhoea, liver, testis and gastrointestinal disease.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We discuss evidence regarding role of chloroquine and hydroxychloroquine in treatment and prophylaxis, use of inhibitors of the renin angiotensin system, safety of ibuprofen, unusual clinical features like gastrointestinal symptoms and interpretation of tests for cardiac enzymes and biomarkers.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>While our conclusions on management of COVID-19 patients with co-morbidities are based on current evidence, however, data is limited and there is immediate need for fast track research.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32247213</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-0334</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><MedlineDate>2020 May - Jun</MedlineDate></PubDate></JournalIssue><Title>Diabetes & metabolic syndrome</Title><ISOAbbreviation>Diabetes Metab Syndr</ISOAbbreviation></Journal><ArticleTitle>Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).</ArticleTitle><Pagination><MedlinePgn>251-254</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1871-4021(20)30052-7</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dsx.2020.03.012</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Multiple issues in management of COVID have emerged, but confusion persists regarding rational interpretation. Aim of this brief review is to review these issues based on current literature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a narrative review with Pubmed and Google Scholar search till 23 March 2020. Search terms were, COVID-19, treatment of coronavirus, COVID 19 and following terms; chloroquine, hydroxychloroquine, ibuprofen, ACE-inhibitors or angiotensin receptor blockers, cardiovascular disease, diarrhoea, liver, testis and gastrointestinal disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We discuss evidence regarding role of chloroquine and hydroxychloroquine in treatment and prophylaxis, use of inhibitors of the renin angiotensin system, safety of ibuprofen, unusual clinical features like gastrointestinal symptoms and interpretation of tests for cardiac enzymes and biomarkers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While our conclusions on management of COVID-19 patients with co-morbidities are based on current evidence, however, data is limited and there is immediate need for fast track research.</AbstractText><CopyrightInformation>Copyright © 2020 Diabetes India. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ritesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Fortis CDOC Hospital, Chirag Enclave, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misra</LastName><ForeName>Anoop</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fortis CDOC Hospital, Chirag Enclave, New Delhi, India; National Diabetes, Obesity and Cholesterol Foundation, New Delhi, India; Diabetes Foundation (India), New Delhi, India. Electronic address: anoopmisra@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Diabetes Metab Syndr</MedlineTA><NlmUniqueID>101462250</NlmUniqueID><ISSNLinking>1871-4021</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D048909" MajorTopicYN="Y">Diabetes Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32247213</ArticleId><ArticleId IdType="pii">S1871-4021(20)30052-7</ArticleId><ArticleId IdType="doi">10.1016/j.dsx.2020.03.012</ArticleId><ArticleId IdType="pmc">PMC7102586</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423</Citation><ArticleIdList><ArticleId IdType="pubmed">30948970</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391</Citation><ArticleIdList><ArticleId IdType="pubmed">32169400</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation><ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785</Citation><ArticleIdList><ArticleId IdType="pubmed">20706626</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiology. 2015;131(2):97-106</Citation><ArticleIdList><ArticleId IdType="pubmed">25896805</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2014 Nov 13;4:7027</Citation><ArticleIdList><ArticleId IdType="pubmed">25391767</ArticleId></ArticleIdList></Reference><Reference><Citation>Vector Borne Zoonotic Dis. 2008 Dec;8(6):837-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18620511</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1969 Mar;4(2):203-14</Citation><ArticleIdList><ArticleId IdType="pubmed">4306296</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Jun 24;48(6):450-455</Citation><ArticleIdList><ArticleId IdType="pubmed">32120458</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 May;94:91-95</Citation><ArticleIdList><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 Mar 17;368:m1086</Citation><ArticleIdList><ArticleId IdType="pubmed">32184201</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2019 Jun 03;8(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">31163625</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res. 2017 Nov;125(Pt A):21-38</Citation><ArticleIdList><ArticleId IdType="pubmed">28619367</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 May - Jun;14(3):211-212</Citation><ArticleIdList><ArticleId IdType="pubmed">32172175</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2020 Jun;69(6):1141-1143</Citation><ArticleIdList><ArticleId IdType="pubmed">32102928</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1981 Jun;78(6):3605-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6115382</ArticleId></ArticleIdList></Reference><Reference><Citation>ScientificWorldJournal. 2014 Jan 14;2014:603409</Citation><ArticleIdList><ArticleId IdType="pubmed">24558317</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 May - Jun;14(3):241-246</Citation><ArticleIdList><ArticleId IdType="pubmed">32247211</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):677-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21550310</ArticleId></ArticleIdList></Reference><Reference><Citation>Gut. 2020 Jun;69(6):1143-1144</Citation><ArticleIdList><ArticleId IdType="pubmed">32139552</ArticleId></ArticleIdList></Reference><Reference><Citation>Viruses. 2018 May 17;10(5):</Citation><ArticleIdList><ArticleId IdType="pubmed">29772762</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2011 Sep;11(9):653-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21550312</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Reprod. 2006 Feb;74(2):410-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16237152</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gesamte Virusforsch. 1972;36(1):93-104</Citation><ArticleIdList><ArticleId IdType="pubmed">4335025</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):100-106</Citation><ArticleIdList><ArticleId IdType="pubmed">32077659</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001A31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32247213
|texte= Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32247213" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |